Take­da over­hauls R&D, fo­cus­ing on Boston and Japan in glob­al re­or­ga­ni­za­tion

New Take­da CEO Christophe We­ber is push­ing plans for a glob­al R&D over­haul, con­cen­trat­ing ef­forts in Japan and the U.S. as the Japan­ese phar­ma com­pa­ny pur­sues three key ther­a­peu­tic are­nas and amps up ef­forts to forge more re­search col­lab­o­ra­tions.

Take­da’s UK op­er­a­tions are com­ing un­der the ax in the re­vamp, with the com­pa­ny be­gin­ning the first “con­sul­ta­tion” stage of the lay­off process. The UK hosts a pre­clin­i­cal R&D op­er­a­tion in Cam­bridge as well as a de­vel­op­ment cen­ter HQ with fa­cil­i­ties in the UK, Switzer­land and Den­mark.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.